Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFaculty of Medicine of Tunis

About this trial

Adhesive capsulitis is a common and disabling shoulder condition characterized by pain and progressive limitation of range of motion. Capsular distension and intra-articular corticosteroid injection are commonly used therapeutic options, often combined with rehabilitation, but their comparative effectiveness remains debated.

The objective of this randomized controlled trial is to compare the efficacy and tolerance of ultrasound-guided capsular distension combined with rehabilitation versus intra-articular corticosteroid injection combined with rehabilitation in patients with adhesive capsulitis.

Outcomes will include shoulder pain, range of motion, functional disability, patient satisfaction, and procedure-related complications, assessed at short, mid, and long-term follow-up.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 80 years

Ability to provide informed consent

Shoulder pain with Visual Analog Scale (VAS) ≥ 40/100

Limitation of external rotation < 45° or < 50% compared to the contralateral side

Disqualifiers

Rotator cuff tear

Previous shoulder surgery

Cervico-brachial neuralgia

Pregnancy or breastfeeding

Trial design

Design model

Parallel

Treatments tested in this trial

  • capsular distension

    Procedure/Surgery

    Ultrasound-guided glenohumeral capsular distension followed by immediate mobilization then a standardized rehabilitation program.

  • Betamethasone (Diprostene®) Injection

    Procedure/Surgery

    Ultrasound-guided intra-articular Betamethasone (Diprostene®) Injection of the glenohumeral joint performed under sterile conditions, followed by a standardized rehabilitation program.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Capsular DistensionExperimental treatment 1 intervention
Group B: Betamethasone (Diprostene®) injectionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Shoulder Pain Intensity (Visual Analog Scale)

Change in shoulder pain intensity assessed using a 100-mm Visual Analog Scale (VAS), where 0 indicates no pain and 100 indicates the worst imaginable pain.

Time frame
Baseline, 1 month, 3 months, and 6 months
2

Shoulder range of motion

Change in active shoulder range of motion measured in degrees, including external rotation, internal rotation, abduction, and forward elevation.

Time frame
Baseline, 1 month, 3 months, and 6 months
3

Shoulder Pain and Disability Index (SPADI)

Change in shoulder pain and disability assessed using the Shoulder Pain and Disability Index (SPADI), a validated 13-item questionnaire scored from 0 to 100, with higher scores indicating greater pain and disability.

Time frame
Baseline, 1 month, 3 months, and 6 months

Secondary outcomes

1

Patient Satisfaction Score

Patient-reported satisfaction assessed using a numeric rating scale ranging from 0 to 10, where 0 indicates not satisfied at all and 10 indicates completely satisfied with the treatment.

Time frame
6 months
2

Procedure-Related Complications

Occurrence of immediate or delayed complications related to the procedures.

Time frame
1 month
3

Rotator Cuff Interval Doppler Signal

Presence of Doppler signal at the rotator cuff interval assessed by shoulder ultrasound, reported as present or absent.

Time frame
Inclusion, 3 months ,6 months
4

Coracohumeral Ligament Thickness

Thickness of the coracohumeral ligament measured in millimeters using shoulder ultrasound.

Time frame
Baseline, 3 months, and 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: